Trial Profile

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Alectinib (Primary) ; Apalutamide (Primary) ; Asciminib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Dabrafenib (Primary) ; Entrectinib (Primary) ; Olaparib (Primary) ; Pemigatinib (Primary) ; Pertuzumab/trastuzumab (Primary) ; Ponatinib (Primary) ; Regorafenib (Primary) ; Tepotinib (Primary) ; Trametinib (Primary) ; Trastuzumab (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
Indications Cervical cancer; Lymphoma; Ovarian cancer; Solid tumours; Uterine cancer
Focus Therapeutic Use
Acronyms FINPROVE

17 Sep 2024 Trial design published at the 49th European Society for Medical Oncology Congress.
30 Dec 2021 Status changed from not yet recruiting to recruiting.
23 Dec 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com